BMY vs LH: fair value comparison
Bristol-Myers Squibb Company and Labcorp Holdings Inc. · Updated 2026-10-19
BMY currently screens as overvalued while LH screens as fairly valued. Within Healthcare, LH currently sits closer to the top of our ranking by discount to fair value. BMY carries the stronger quality grade.
| BMY | LH | |
|---|---|---|
| Verdict | Overvalued | Fairly valued |
| Last price | $59.12 | $312.15 |
| 12-month range | $42.60–$68.09 | $246.64–$339.34 |
| Rank by discount to fair value | #72 of 108 Healthcare | #69 of 108 Healthcare |
| Quality grade | B | D |
| Leverage | High | Moderate |
| Margin trend | Expanding | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Neutral |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BMY fair value analysis · LH fair value analysis